TB Alliance to receive drug candidate compounds from Novartis
According to the World Health Organization, there are more than 8.6 million cases of tuberculosis each year, with more than 1.3 million deaths reported annually. TB is a
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
To determine the effectiveness of FlunisynTM ITS produced its own live influenza challenge agent derived from the recently circulating Influenza A/California/2009 (H1N1) virus. This challenge virus, manufactured in
The goal of the collaboration is to commercialize proprietary formulations of nature-identical synthetic astaxanthin products with pharmaceutical-grade purity that will provide improved oral bioavailability compared with other astaxanthin